standardization, and to suggest improvement in these practices.
Data Sources.-The material is based on survey results from 546 US laboratories, review of the literature from 1988 to 2011, and the College of American Pathologists Web site for consensus comments and additional survey questions.
Conclusions.-Cytologic-histologic correlations can be performed retrospectively, during initial case review, or both. At minimum, all available slides should be reviewed for a high-grade squamous intraepithelial lesion Papanicolaou test with negative biopsies. The preferred monitor for correlations is the positive predictive value of a Papanicolaou test. Laboratories should design cytologic-histologic correlation programs to explore existing or perceived quality deficiencies.
(Arch Pathol Lab Med. 2013;137:199-213; doi: 10.5858/ arpa.2012-0250-OA) T he Clinical Laboratory Improvement Amendments of 1988 (CLIA) requires ''Laboratory comparison of clinical information, when available, with cytology reports and comparison of all gynecologic cytology reports with a diagnosis of high-grade squamous intraepithelial lesion (HSIL), adenocarcinoma, or other malignant neoplasms with the histopathology report, if available in the laboratory (either on-site or in storage), and determination of the causes of any discrepancies.'' 1 This requirement is generally referred to as cytologic-histologic correlation (CHC). The rule allows laboratories the latitude to develop a process of correlation that is best suited to their resources, staffing, and workflow. However, it is difficult for laboratories to compare themselves to one another when methods of correlation and recording data differ. The College of American Pathologists (CAP) and others have investigated national laboratory practices in CHC and found significant variability in practice. 2, 3 The point at which correlation occurs, the method of correlation, the data collected, and the manner of data recording lack standardization. The ''2010 CAP Laboratory Accreditation Program Cytopathology Checklist'' 4 provides some guidance for the performance of CHC. The checklist requires that laboratories document the resolution of significant discrepancies in an addendum report or confidential quality assurance (QA) document (CYP.01900), that significant discrepancies affecting current patient care result in a corrected report (CYP.07530), that laboratories make an effort to obtain reports or materials for review in cases where HSIL or malignancies are reported on Papanicolaou (Pap) tests (CYP.07543), that if such materials and reports are not available in the laboratory, an attempt is made to obtain these (CYP.07556), and that laboratories correlate gynecologic cytologic findings with available clinical information (which might include biopsy results) (CYP.07569). 4 Although these guidelines represent good laboratory practices and protect patient safety, what is lacking is a means of using these data for interlaboratory comparison and continuous quality improvement. The Centers for Disease Control and Prevention subsidized a grant to describe current gynecologic cytopathology quality practices and to facilitate practice standardization, which was awarded to the CAP in 2009. The outcome of that effort as applied to CHC is described in this article.
MATERIALS AND METHODS
The CAP conducted a survey of existing gynecologic cytopathology practices from 1245 US laboratories and tabulated the results from the 546 completed surveys (43.9% response rate), which were then posted on a CAP Web site. Eighteen questions, some with subsections, focused specifically on CHC. Additionally, 4 inquiries relating to CHC were included as a subsection in questions on general quality practices. Stakeholders from the cytopathology community were contacted by e-mail and invited to comment on the findings and answer additional questions posted on the Web site. Quality practices were organized under 5 major topics, and each was assigned to a working group composed of pathologists, cytotechnologists, and staff from CAP and the Centers for Disease Control and Prevention. Each working group performed a literature search, reviewed survey results, suggested additional follow-up questions, and analyzed survey results to construct consensus statements for quality practices in their topic. The working groups presented their findings and proposed consensus statements at the Gynecologic Cytopathology Quality Consensus Conference (GCQC2), where modification of the statements occurred after participant input and group voting. Tworek et al 5 discuss this process in greater detail. Working Group 4 was responsible for CHCs. We ran a literature search on PubMed (US National Library of Medicine, Bethesda, Maryland) and MedScape (New York, New York) between 1988 and 2011 using the search words gynecologic, cytologic histologic correlation, cytological histological correlation, cytohistologic correlation, cytology correlation, Pap test, Papanicolaou smear, Pap smear, cervical cytology, and cervicovaginal cytology, and further searched on selected citations linked to pertinent articles. Thirty-three potentially relevant articles were divided among the working group members to summarize the findings. Group members also summarized national survey findings from 4 statistical tables of general quality data, 15 statistical tables specifically related to questions on CHC, and 24 tables collating the results of public opinion and comments from the Web-based postsurvey period. After extensive discussion, we crafted 8 consensus statements for presentation at the meeting and invited audience voting on the statements as agree or disagree, or as follows: (1) agree as stated, (2) disagree-not robust enough, or (3) disagree-too restrictive. We reworded selected statements and voting choices after our initial presentation and after audience feedback, with repeat voting on 4 areas (statements 1, 2, 4.2, and questions concerning additional interpretations that should be included in positive predictive value [PPV] statistics).
RESULTS
In the general quality section of the national survey, CHC tied for first place among 15 quality metrics considered useful in a QA program, along with multiheaded case review of difficult cases and retrospective review of negative for intraepithelial lesion and malignancy (NILM) slides in current HSIL Pap test cases, with participants ranking CHC 4.2 on a scale of 1 to 5, from not useful to very useful. Most laboratories (64.8%; 291 of 449) use laboratory-defined limits to initiate investigative actions into variances in CHC performance (Table 1) . Almost 30% (132 of 448) use rate change as a trigger to investigate variances. Very few laboratories rely on statistical analyses based on standard deviation (8.5%; 38 of 449) or variance from a mean (7.6%; 34 of 449). Interestingly, few laboratories (15%; 20 of 133) take any corrective action for Pap test-cervical biopsy correlation rate as compared with other quality monitors. For the 88.8% (459 of 517) of laboratories that generate periodic cytopathology quality reports, 63.7% (291 of 457) include CHC rates in the report.
Laboratories had the option of multiple responses for some of the 18 questions in the survey related specifically to CHC; however, 93.8% (480 of 512) of laboratories responding actively monitor correlations between Pap test and biopsy results. Nearly all laboratories (95.4%; 497 of 521) that monitor CHC also interpret cervical biopsies or have access to follow-up of cervical biopsies for review. Reactions to discrepancies between Pap test and cervical biopsy results varied (Table 2) , with 67.3% (315 of 468) of the laboratories investigating and/or resolving the discrepancies during biopsy sign-out, 60.5% (283 of 468) addressing the discrepancy in the biopsy report, and 57.7% (270 of 468) performing retrospective review of cases for correlation statistics and investigating any discrepancies at that time. Multiple answers were allowed for this question, and it is clear from the answers that laboratories address discrepancies in many ways. Rarely, however, does the pathologist signing out the Pap test always sign out the cervical biopsy (5.6%; 26 of 468). Most laboratories (84.4%; 395 of 468) have a written policy requiring retrospective review of cases to investigate discrepancies, whereas 70.3% (329 of 468) have a policy requiring investigation or resolution during biopsy sign-out, and 67.9% (318 of 468) address discrepancies in Respondents commented that the major barriers to implementing such policies were lack of sufficient pathologists on site, the amount of work involved for little gain, the expense of recuts, time constraints, and separation of facilities where the work occurs. Participants reported that cervical biopsies were sometimes (44%; 12 of 27) or rarely (33%; 4 of 27) unavailable for a retrospective review along with Pap tests. The most frequent scenario (48%; 13 of 27) for CHC in laboratories is ''bidirectional'' correlation; that is, CHC is initiated by either a Pap test result or a cervical biopsy result and are integrated (Table 6 ). Additionally, 77% (20 of 26) of the laboratories review all available glass slides for both the biopsy and cytology in discordant cases (multiple responses allowed), 19% (5 of 26) review all available slides for all cases where there is a Pap test and a subsequent biopsy, whether concordant or discordant, and 15% (4 of 26) review only cytology slides of discordant cases, but record correlation statistics overall. One individual commented that glass slide review is at the discretion of the pathologist, even though concordances and discordances are recorded. Another commented that correlations are prompted by clinicians. As for the optimal time to perform CHC, 59% (16 of 27) preferred prospective (during initial biopsy interpretation) and 30% (8 of 27) preferred retrospective review, whereas 11% (3 of 27) stated ''other,'' with comments that both times are appropriate and that prospective review is not possible in all systems but is preferred for patient care. One-half (14 of 28) of respondents approve of standardizing CHC among laboratories, but 32% (9 of 28) are unsure of the advantages. Of those that prefer standardization, 72% (13 of 28) would like guidance on the type of statistics for all laboratories to maintain, 67% (12 of 18) seek acceptable actions for discrepancies and statistical outcomes, 61% (11 of 18) would like to standardize the acceptable discrepancy rate between Pap test and biopsy results, and 50% (9 of 18 seek a time-frame limit from abnormal Pap test result to cervical biopsy for correlations. Participants were divided on whether pathologists should provide recommendations in a biopsy report when a cytologic interpretation is positive and the biopsy is negative: 48% (13 of 27) said yes, 22% (6 of 27) said no, and 30% (8 of 27) were unsure. Most respondents (62%; 16 of 26) would welcome standardized comments for follow-up recommendations in a biopsy report when the Pap test interpretation is positive but the biopsy is negative. Approximately one-half (52%; 14 of 27) responded that the Pap test review should be recorded in the biopsy report when a Pap test is NILM and the biopsy is HSIL, but 41% (11 of 27) did not agree. For those that wanted a statement in the biopsy report regarding that review, 50% (8 of 16) wanted the statement to indicate the additional measures taken on the biopsy to resolve the discrepancy, 38% (6 of 16) would report the results of the Pap test review and who reviewed it, 38% (6 of 16) wanted only a statement that the Pap test was reviewed but not the result of the review, and 12% (2 of 16) wanted only a statement that a discrepancy between the Pap test and biopsy exists. One participant commented that the statement should include information about the false-negative (FN) rate of Pap tests and its causes; 63% (17 of 27) of respondents would like laboratories to be mandated to rescreen NILM Pap tests when prompted by a CIN 2-3 or cancer biopsy, in the same manner that is required for HSIL Pap tests. When asked how to proceed if a Pap test error is found by that review, 48% (11 of 23) preferred in-house review of any misinterpreted Pap tests by the laboratory staff for educational purposes as the appropriate corrective action, 22% (5 of 23) preferred that the finding be documented in a QA report, 13% (3 of 23) would review the misinterpreted Pap test with the original cytotechnologist, and 13% (3 of 23) would issue an amended report if the review yielded an abnormal Pap test finding. Only one answer was allowed for this question. We queried individuals on perceived barriers to performing CHC statistical metrics within their laboratories, allowing multiple answers. The most common barriers cited were difficulty obtaining necessary data from the laboratory information system (LIS) or other LIS limitations (48%; 12 of 25), lack of dedicated QA personnel (44%; 11 of 25), lack of a system to compile and analyze data (32%; 8 of 25), inability to access all of the biopsy slides (32%; 8 of 25), uncertainty as to how to improve established metrics (28%; 7 of 25), and complexity of the exercise (24%; 6 of 25). Most respondents (78%; 18 of 27) had some difficulty collecting correlation data using LIS applications: 52% (14 of 27) had a report generator for correlations but performed at least some of the correlation manually, 26% (7 of 27) did not have an LIS that collected correlation data or accepted manual entry of correlation data, and 15% (4 of 27) had to collect data manually and enter it into the LIS. Most (59%; 16 of 27) did not have an application that reported correlation data, and slightly more than half (52%; 14 of 27) did not have an LIS that provided patient-tracking functions, although most (48%; 13 of 27) performed patient tracking manually. Furthermore, slightly more (59%; 16 of 27) did not have an LIS that allowed for inquiry of the patient's caregiver regarding patient status, such as follow-up visits, biopsies, transfer, or discontinuation of care.
We developed the 8 consensus statements in Table 7 based on these data, the literature, and group discussions. Almost all of the statements received initial agreement (defined as .70% agreement) at the consensus conference Statement 4.2, inquiring whether laboratories should use the PPV for the whole laboratory to formulate QA monitors, did not achieve consensus agreement. For purposes of reporting on consensus, the working groups decided that 70% to 79% of votes represented agreement, 80% to 89% indicated moderately strong agreement, 90% to 98% was strong agreement, and 99% or better indicated nearly complete agreement. An additional question was formulated during the conference to determine what atypical Pap test interpretation values should be included in the calculation of the PPV. These results are shown in Table 8 . No consensus was achieved for including atypical Pap test results into the PPV.
Comment
Cytologic-histologic correlation was originally mandated through CLIA as a measure of cytology interpretive performance but is of equal value as a measure of biopsy interpretation performance and laboratory process assessment. It is a true system monitor that provides outcome information. Cytologic-histologic correlation for gynecologic pathology serves 2 broad purposes in QA; it (1) provides critical and timely information for patient management by confirming or resolving Pap-biopsy discrepancies, and (2) provides a general mechanism to monitor the entire process of the laboratory to improve the overall interpretive quality of cervical cytology and histology. Cytologic-histologic correlation is not a pure assessment of the performance of either test (Pap tests or cervical biopsies) because of the innate variables of both. There is poor interobserver concordance for certain interpretations of both Pap test slides and cervical biopsies. [7] [8] [9] [10] [11] [12] [13] Biopsies are also not the best gold standard, 14 and colposcopic detection of HSIL or cancer is not very sensitive. [15] [16] [17] [18] The major cause of discordant pairs in CHC remains sampling error. In the largest study to date, 2 to our knowledge, 85.2% of FN (1230 of 1444) and 94.6% of false-positive (FP; 1445 of 1527) Pap test results were due to sampling error. Despite decades of improvement in Pap test technologies, including liquidbased cytology preparations, triage for human papillomavirus testing, and automated screening, biopsy and cytology sampling error rates remain fairly constant in gynecologic cytology. 19 The first question that we addressed as a working group was, ''When is the best time to correlate Pap test and biopsy cases?'' Most of the laboratories surveyed investigated discrepancies both at initial biopsy interpretation (67.3%; 315 of 468) and during a retrospective review for correlation purposes (57.7%; 270 of 468), with more than one-half (60.5%; 283 of 468) of the laboratories addressing discrepancies in a biopsy report. This implies that cytologists recognize that CHC serves multiple purposes. Correlation prompted by an abnormal cervical biopsy result with resultant review of prior discordant Pap test slide describes a QA review of the Pap test that, in most cases, has no immediate effect on the care of that patient but may reveal diagnostic variances or interpretation trends. Correlation prompted by a normal biopsy pursuant to an abnormal Pap test result constitutes investigation of the discordance that may affect patient outcome.
For purposes of this discussion, ''real time'' correlation is defined as the process of reviewing Pap test slides or results when a cervical biopsy is initially examined and interpreted. ''Retrospective'' correlation refers to the process of reviewing the Pap test and cervical biopsy slides or results after conclusively reporting both specimens.
Consensus Statement 1: Cytologic-histologic correlation may be performed in real time, retrospectively, or both.
Real-time correlation preferentially affects immediate patient care and is strongly preferred for a HSILþ (encompassing HSIL, adenocarcinoma in situ, squamous or glandular carcinoma) Pap test result and subsequent negative biopsy finding. Real-time correlation allows the pathologist to annotate confirmation of the Pap test interpretation in the biopsy report and to contact the clinician regarding the evaluation findings of both. For HSILþ Pap test results with negative cervical biopsies findings, real-time correlation promotes further evaluation of the biopsy, such as additional levels, ancillary staining, or reorienting tissue in the block. It permits rapid subsequent follow-up with the patient. This approach also distributes CHC among the staff reporting cervical biopsies, thereby serving an educational purpose, provided staff is aware of the human tendency toward confirmation bias in favor of the cervical biopsy result. Potential barriers to this approach are review bias, difficulty tabulating correlation statistics from many pathologists and reports, unavailable Pap slides and/or Pap test reports, and documentation of the review. Some laboratories prefer to keep QA activities and data separate from diagnostic activities and not to record the results of review in a biopsy report. In the survey, 84.4% (395 of 468) of respondents had a written policy requiring retrospective CHC for statistical purposes but only 57.7% (270 of 468) reviewed cases retrospectively. This may imply that some laboratories primarily review report results, not slides, for retrospective correlation. Some laboratories may comment on either discrepancies or concurrences in the biopsy report but not both. In the survey, 52.9% (266 of 503 of laboratories did not have a policy that addressed concurrences in the biopsy report. For those laboratories that perform real-time CHC but do not make comments in the biopsy report, it may be necessary to provide separate data collection worksheets to pathologists interpreting cervical biopsies so that information can be documented and periodically tabulated.
For those that do document CHC in the biopsy report (47.1%; 237 of 503), it may be useful to format standardized comments, perhaps adding educational information on the Pap test false-negative rate or PPV. Cioc et al 20 standardized their laboratory's definition of CHC discrepancies, required correlation before report issuance, and included standardized text as comments to identify discrepancies in the biopsy report. They concluded that the exercise was valuable in directing the management of individual patients. Only 37.9% (187 of 494) of laboratories had policies requiring recommendations for clinical follow-up for discrepant cases. This may reflect reluctance to advise caregivers without comprehensive clinical knowledge about the patient's condition.
Retrospective CHC is acceptable for laboratories that do not have immediate access to Pap test results or cervical biopsy findings or for those laboratories where it is logistically untenable to perform concomitant review. Retrospective CHC is usually accomplished by generating a comparative report from the laboratory information system (LIS) that lists prior Pap test results obtained from patients with a cervical biopsy taken within a given interval. The interval may be monthly, quarterly, semiannually, or annually, depending on the laboratory's volume and resources. Shorter intervals are preferred primarily to allow for timely feedback to caregivers if real-time correlations 
Alternatively, there may be caregiver bias against a correct HSIL Pap result because of reluctance to act aggressively to obliterate the lesion when biopsy findings are negative or a lower grade. A second pathologist's confirmation of the initial Pap test interpretation of HSIL may prompt further investigation. Our focus is on an HSIL interpretation because it has the greatest significance for the patient: it indicates a lesion with premalignant potential. Low-grade lesions may be followed longitudinally and do not necessarily require biopsy or excision. 21 For real time CHC, the pathologist should ensure that the biopsy is adequate for evaluation and is truly negative. Bewtra 
squamous intraepithelial lesion (SIL), 38% (n ¼ 13) had no transformation zone, 26% (n ¼ 9) had inadequate sectioning into the block as determined by a mismatch between gross and microscopic biopsy size, 18% (n ¼ 6) had complete epithelial denudation, and 15% (n ¼ 5) had orientation problems. Correction of some problems, including additional block levels and tissue reorientation, resulted in one-third of the cases (32%; 11 of 34) demonstrating SIL. 22 Most of their biopsies were obtained within 18 weeks of the Pap test, but none of the 3 biopsies obtained between 12 and 58 weeks of the Pap test showed SIL, even after additional measures to improve the specimen. Review of the glass slides was necessary to detect these quality deficiencies in procurement and preparation.
Pathologists have no control over when a patient has a biopsy performed, and the 3 to 4 month preferred and 6-month maximum intervals refer to the target interval for laboratory correlation, not to when the patient receives a biopsy. For real-time CHC, an HSILþ cervical biopsy is the initiating event, and laboratories should correlate that biopsy with the most abnormal prior Pap test result taken within the previous 6 months. Papanicolaou test results from the time of the biopsy should be excluded unless no earlier Pap test result is available. Several studies have demonstrated low concordance between Pap test results and biopsy findings obtained concurrently. [23] [24] [25] Papanicolaou tests performed concurrently and correlated with the biopsy result in a higher false-negative rate, presumably because Pap test-accessible cells have already been removed by a previous Pap test. Endocervical curettages that do not show SIL, adenocarcinoma in situ, or cancer do not require correlations because the target zone is higher than the transformation zone sampled with the Pap test. Endocervical curettages that do show SIL, adenocarcinoma in situ, or cancer should be correlated with the Pap test because a lesion has been detected by the biopsy.
When CHC is performed retrospectively, the laboratory should correlate the incident Pap test (the first Pap test with HSILþ) with the most abnormal tissue biopsy result obtained within 6 months after the incident Pap test, preferably within 3 to 4 months. Longer intervals allow lesions time to regress (especially when low-grade lesions are included in correlations) and result in a higher discrepancy rate. Patients may have interval therapy or biopsies elsewhere when the interval window is extended beyond 6 months. If a patient has not had a biopsy within 6 months of a HSILþ Pap test, it is prudent to notify the caregiver. As above, Pap tests performed concurrently with the biopsy should not be correlated unless there is no record of, or access to, the incident Pap test. It is appropriate to include loop electrocautery excisional procedure, conization, and hysterectomy cervical specimens in the correlation because these may expose a higher-grade lesion than found in the initial biopsy. Laboratories performing retrospective CHC but not real-time correlations should strive to perform the correlation in a timely manner that can influence subsequent patient management. If laboratories search for the biopsy results for an abnormal Pap test finding in an interval that is too short (eg, 2 weeks), there may not be sufficient time for that patient to have had biopsies. Conversely, performing retrospective CHC annually is unlikely to have an immediate effect on the management of an individual patient because her care would have proceeded without intervention by the pathologist. In some cases, such as when the woman is pregnant, a longer biopsy interval is more likely to capture subsequent biopsies because it is acceptable to defer the biopsy until the postpartum period. Lack of biopsy follow-up in the pregnant population should not be construed as clinical mismanagement. For those pathology practices with a robust pregnant population, it may be preferable to monitor the CHC of that population separately. Review of both the biopsy and the Pap test slides has moderate support from the cytopathology community; 57.7% (270 of 468) of laboratories surveyed investigate discrepancies using retrospective review of cases, and 67.3% (315 of 468) investigate or resolve discrepancies during biopsy sign-out. In the postsurvey Web-based, public comments, 77% (20 of 26) of the participants microscopically reviewed both Pap test and biopsy slides in discordant cases, but if the biopsy was not available, then only the Pap test was reviewed (59%; 19 of 32). One-quarter of laboratories (8 of 32) made attempts to obtain the biopsy if it existed at another laboratory. More than one-half (66%; 19 of 29) obtained additional biopsy levels to expose a lesion deeper in the block, and 48% (14 of 29) did so because they suspected dysplasia on initial biopsy evaluation. However, one-quarter of respondents (7 of 29) did not obtain additional levels of biopsies to resolve discrepancies. The number of postsurvey, Web-based comments was low (N ¼ 32) and may not represent the cytopathology community as a whole. When the participants at the GCQC2 were polled to comment on the statement ''The correlation interval between the Pap test and the biopsy should be preferably within 3 to 4 months, but no greater than 6 months,'' 89% (59 of 66) agreed (as stated), 3% (2 of 66) disagreed (too long), and 8% (5 of 66) disagreed (too short). When answer selections for participants were changed, 73% (40 of 55) agreed (as stated), 5% (3 of 55) disagreed (not robust enough), and 22% (12 of 55) disagreed (too restrictive). This demonstrates that most participants agree with the intervals, but nearly one-quarter would prefer to establish their own intervals.
Consensus Statement 3: Standardization of CHC and its metrics is desirable.
From the survey, one-half of respondents (14 of 28) would like to see standardization of CHC correlation, and statement 3 was strongly supported (94% agreement; 59 of 63) in the conference. Most those in favor (72%; 13 of 18) sought guidance on the type of statistical metrics to maintain and requested specific actions (67%; 12 of 18) and statements (62%; 16 of 26) to follow-up discrepancies. Vrbin et al 3 polled 162 laboratories participating in CAP programs to determine similarities and differences in their CHC practices and predetermined 15 ''minimally expected'' data points plus additional data points that they thought would be part of routine practice. Of the minimally expected data points, more than one-half of the laboratories recorded the cytology case number (58 of 70; 89.9%), cytology diagnosis (50 of 70; 71.4%), surgical case number (43 of 70; 61.4%), and surgical diagnosis (42 of 70; 60%). No other data points were collected by more than 50% of laboratories, and 17% (9 of 52) did not record the data on forms, logs, or tally sheets. Vrbin et al 3 concluded that CHC standardization is lacking in the cytology community and suggested forms that record minimum variables.
One of the goals of our working group was to define the minimal expectations for performing gynecologic CHC, including the steps in the process, the types of specimens to correlate, the intervals for correlation, and the data to collect. These recommendations are the focal point of this article. We discovered during our literature review that CHC outcomes are difficult to compare because of the lack of standardization in process and reporting. We also recognized the value in allowing laboratories flexibility to design their own CHC correlation processes. Using the example of the pregnant population, laboratories receiving a high volume of obstetric Pap tests could perform separate CHCs for that group, with longer correlation and provider notification intervals. Laboratories vary greatly on the statistical measures that they record. The national survey revealed that approximately one-quarter of laboratories monitored these statistics polled: Pap test sensitivity (22%; 87 of 392), Pap test specificity (19%; 76 of 392), screening sensitivity (22%; 86 of 392), and interpretive sensitivity (22%; 87 of 392). Most of the laboratories ranked the value of these statistics as a 4 or 5, using a scale of 1 to 5, with 1 as least valuable and 5 as most valuable. Therefore, most believe that the effort of generating a statistical assessment of CHC is worthwhile but struggle with what to record and what to do with the values assessed. We were surprised to find that 12% to 22% of laboratories calculate these statistics for cytotechnologists and for pathologists (6%-12%), albeit less often. Further statistical tests showed that these measures were monitored primarily by larger laboratories, perhaps because they have the resources to do so and to use them as performance measures. These monitors may be applicable to individuals in large laboratories, provided the case volume is large enough to make a fair assessment of individual performance, but for most laboratories, discrepancy values are too small to be statistically valid for individuals. It might be appropriate to monitor individual statistics in large laboratories when they identify an overall change in laboratory statistical performance, identify themselves as an outlier in comparison with laboratory benchmark statistics, or suspect poor individual performance because of reviewing other cytology QA monitors. Such efforts should be used cautiously because of the poor reproducibility documented for certain biopsy and Pap test interpretations. If laboratories continue to monitor screening and interpretive sensitivity, they must implement processes and policies that exhaust all prereporting correlation activities (eg, additional sections from paraffin blocks, reorientation of specimen in the block, and second pathologist review) before classifying a pair as a diagnostic Cytologic-histologic correlation data present a statistical challenge because patients with negative Pap test results do not have biopsies performed, so there are generally no correlations for negative Pap test results. This limits the meaningful statistical monitors that can be calculated to the PPV, because there is no measure for a true-negative or false-negative Pap test result. The sensitivity of a Pap test is the ideal metric for this screening test, but because of the limited number of negative Pap test correlations, it is a biased metric. As noted in Table 9 , once negative Pap test metrics are removed from the matrix, sensitivity and specificity cannot be accurately calculated, and only the PPV remains. This assumption is supported by data from the 2010 College of American Pathologists Gynecologic Cytology Outcomes: Biopsy Correlation Performance Q-Tracks 26 for 48 participating laboratories, where sensitivity was calculated from the total number of FN correlations. Of these laboratories, 11 (23%) did not have any correlations with negative Pap tests and the median number of correlations with a negative Pap test was 6. This total is further reduced if the calculations exclude Pap tests procured concurrent with biopsies, as we recommend. False-positive Pap test results are overrepresented in most laboratories because of the lack of negative Pap test correlations and the pervasiveness of sampling error, but true-positive (TP) and FP totals are the data that are most readily available. For a valid statistical analysis of PPV, a minimum of 20 events is necessary, so CHC statistics will require collection over time to produce enough positive and negative correlation pairs for statistical significance for the laboratory as a whole. Positive predictive value is also independent of disease prevalence, enhancing its value for interlaboratory comparison for laboratories that primarily serve women with a high risk for dysplasia, such as clinics serving populations with sexually transmitted disease or human immunodeficiency virus. Several studies, including the largest study examining CHC statistics by Jones and Novis, 2 have shown that the PPV for laboratories is between 71% and 94%, with a median of 83% to 89%. 19, 24, 27 These values may change as caregivers adopt the recommended consensus guidelines for LSIL and defer biopsies of those lesions, thereby reducing the number of positive correlations for statistical purposes. Laboratories that consistently demonstrate a PPV between 95% and 100% would not necessarily represent the best laboratories-they may be underinterpreting SIL and should investigate their laboratory's SIL metrics. A high PPV could indicate identification of only the most obvious lesions in both specimens and may constitute underrecognition of subtle lesions. Correlation with colposcopy might reveal hesitancy to biopsy subtle colposcopic lesions. One shortcoming of the PPV calculation is that it assumes that the biopsy interpretation is always correct. Studies have shown that potentially FP Pap test results with negative cervical biopsies followed by conization or loop electrocautery excisional procedure reveal SIL in up to 89% of women. [28] [29] [30] [31] [32] [33] [34] A low PPV should prompt investigation of the cytologic diagnostic accuracy and intradepartmental interpretive variability. Investigation of cytologist's metrics, such as the ASC:SIL ratio; concordance with QA rescreening results; rates in diagnostic categories; and concordance of pathologists and cytotechnologists may reveal the underlying cause of a low PPV. Microscopic review of selected cases, with a group consensus slide review or group educational review, should help to pinpoint areas for improvement. Cytologic-histologic correlation statistics are best analyzed in conjunction with other cytopathology metrics and, where possible, clinical colposcopic metrics to determine the cause of errors.
The primary role of a Pap test is as a screening test to identify women who require further clinical follow-up. Any abnormal Pap test result has served that purpose. For the purpose of standardizing the PPV, we propose that a positive correlation represent any biopsy interpretation and any Pap test interpretation, in any combination, from the ''positive'' list in Table 10 . By calculating the PPV using a 
Abbreviations: FN, false-negative; NPV, negative predictive value; Pap, Papanicolaou; PPV, positive predictive value; TN, true-negative TP, truepositive.
broad definition for positive, laboratories minimize the interobserver variability that is innate in the interpretation of SIL in both Pap tests and biopsies. Atypical Pap test interpretations, such as ASC-US, ASC-H, and AGC (including endocervical or endometrial glandular abnormalities) are excluded. A negative correlation is any normal, negative, or reactive biopsy result with a Pap test result from the first column in Table 10 or any NILM, reactive, or infectious Pap test result with a biopsy result from the second column in Table 10 . Negative correlation pairs (samples from the same patient) represent the CHC discrepancies that may be targeted for microscopic review. A FP Pap test result, then, is any positive Pap test result from the list in Table 10 with a corresponding negative biopsy result. Even though microscopic review of the FP Pap test result reveals that the initial interpretation is correct, it remains a FP test for purposes of PPV statistics. Laboratories may tabulate the results of microscopic review of the pair and the finding of a correct interpretation separately as a measure of biopsy sampling error. Where possible, PPV statistics should capture only one final result per patient (one pair). This may be difficult if laboratories do not have access to the results of all related procured specimens for that patient over a given timeline. Original interpretations of both the Pap test and any biopsies, rather than secondary microscopic review interpretations, should be used for correlation statistics. Finally, PPV is most valid as a laboratory metric, not an individual metric, specifically because it is difficult to collect enough correlation pairs for each individual interpreting cytology or biopsy results and because review for accuracy of interpretation does not play a role in calculating the metric. Most participants (70%; 44 of 63) in the GCQC2 conference agreed that the PPV is the preferred metric for monitoring CHC, but only slightly more than one-half (58%; 32 of 55) wanted to use the PPV to formulate QA monitors, with 29% (16 of 55) believing that that statement was too restrictive. This was the lowest consensus vote for the CHC topic and may be related to uncertainty as to how to apply PPV to develop new monitors or reluctance to introduce new monitors when the QA requirements of the laboratory already represent significant additional workload. Participants also wanted a voice in what diagnostic interpretations to include in PPV calculations, and we agree that each laboratory should have the freedom to define a PPV for internal use. After formulating several inquiries related to this question, participants voted again, with the results summarized in Table 8 . Slightly more than one-half wanted to include ASC-H (55%; 27 of 49) and AGC (54%; 28 of 52) in the calculation, which we do not consider consensus. It is understandable that participants would want to include ASC-H and AGC because these interpretations are often associated with significant lesions, and the laboratory is identifying an abnormality in the Pap test result. We maintain PPV should be calculated as described above for purposes of interlaboratory comparison because of the significant amount of literature supporting an approach excluding atypical interpretations. We emphasize that atypical interpretations are poorly reproducible, represent many entities, and cannot be proven with a biopsy. However, that does not exclude laboratories from calculating PPV with and without ASC-US, ASC-H, or AGC. On the contrary, we encourage laboratories to pursue CHC investigation of biopsy outcomes for ASC-US, ASC-H, and AGC as one of the follow-on monitors that might help to explain initial PPV results. Aside from representing a simple way to monitor CHC, a standardized PPV can show trends and help the laboratory to develop further QA investigations.
Consensus Statement 5:
It is desirable to provide timely notification to a caregiver for confirmation of a negative biopsy result and an HSIL or cancer Pap test result, or for a negative biopsy finding and a HSIL or cancer Pap test result reinterpreted as NILM.
Caregivers encounter many barriers that make it difficult for them to be aware of, or follow-up on, abnormal Pap test and biopsy results. 35, 36 Both of the above clinical situations can adversely affect patient care. In the case of a negative biopsy finding and an HSILþ Pap test result, the caregiver may be inclined to believe the colposcopy and biopsy results without further investigation, and the patient may continue to harbor an undetected high-grade lesion and be lost to follow-up. Anderson and Jones 37 found that 45% (24 of 53) of the FP Pap tests in their study of 68 Papþ/biopsyÀ cases showed subsequent SIL with additional biopsies. In the case of a biopsyÀ/HSILþ Pap test, whereby reevaluation of the Pap test discovers an interpretive error, the patient can be spared an invasive procedure if the caregiver is informed. Both circumstances require timely CHC and both involve potential HSILþ interpretations because low-grade lesions no longer require ablation in most situations. 6 The conference participants strongly supported these actions ( Table 7) . Documentation of caregiver notification may be in the biopsy report, cytology report, or in a separate QA document.
Consensus Statement 6: When you do not have biopsy results for a HSILþ Pap test, the best way to obtain follow-up is to send a formal request for this information to the caregiver that collected the Pap test.
This statement also garnered moderately strong conference consensus (87%; 55 of 63) after modification during the conference from the original statement, ''Laboratories should attempt to obtain correlation biopsy information for all patients with a HSILþ Pap test.'' It is supported by a CAP Laboratory Accreditation Program guideline (CYP.07556) requiring laboratories to document efforts to obtain follow-up histologic information for CHC when HSILþ Pap test results are reported and the follow-up biopsy is not available in the laboratory. 4 The CLIA regulation ( §493.1274[c] [5] [iv]) requires only that laboratories record the total number of HSILþ Pap cases for which biopsy results were available for comparison, 1 which may explain the survey results, where only 83% (422 of 508) of laboratories have a written policy on how to proceed if no follow-up biopsy is received for a HSILþ Pap test, and of those, 91% (320 of 351) notify the caregiver's office. Despite CLIA requirements, in the postsurvey, Web-based comments, only 75% (24 of 32) of respondents found it useful to track the percentage of HSILþ cases for which follow-up is received, perhaps because further efforts by the laboratory to obtain that information may prove futile or because there is little more that laboratories believe they can do with those data. This recommendation serves 2 purposes: it ensures that the caregiver is aware of a HSILþ Pap test result on his or her patient, and it provides the laboratory feedback on the accuracy of the Pap test interpretation. Not all laboratories will have access to biopsy results on some or all of their patients, but they can ask for that information in a variety of ways that might include a generic statement in the cytology report requesting biopsy results. Additionally, laboratories should define the interval within which followup data should be sought. Laboratories notified caregivers, on average, within 5 months (range, 0-45 months). We suggest that this interval mirror the CHC interval of no less than 6 months to affect patient outcome. Regardless of the method used to obtain follow-up information, it should be described in a written procedure, and subsequent correlation results should be documented in the QA program. Consensus Statement 7: Microscopic review of all slides from discordant Pap test/cervical biopsy pairs (as laboratory-defined) is desirable for CHC.
Microscopic review of discordant slides is a common means of correlation and investigation of CHC discrepancies in the literature. [38] [39] [40] It is also a method of evaluating sectioning, embedding, cutting, staining, and interpretation of tissues and processing, staining, screening, and interpretation of Pap tests. Laboratories should determine what constitutes a discordant Pap-biopsy pair requiring microscopic review beyond an HSILþ Pap/normal biopsy pair, define their own additional noncorrelation metrics for their QA programs, and review all available slides. If slides are not available for review, the original interpretation is assumed to be correct and stands as the review interpretation for correlation recording purposes. In the survey, approximately one-half of respondents (253 of 493) had a written policy requiring review of NILM Pap tests when a CIN is discovered on biopsy. The level of biopsy abnormality prompting the review was 39% (118 of 304) for CIN 1, 88% (266 of 304) for CIN 2, 92% (281 of 304) for CIN 3 and 90% (274 of 304) for squamous cell carcinoma. A high percentage included adenocarcinoma in situ (86%; 262 of 304) and adenocarcinoma (80%; 242 of 304) as triggers for NILM Pap test review, even though the Pap test is intended as a screening test for squamous lesions. These high reporting rates may be due to the inclusion of these discordances into retrospective CHC, rather than an extended application of the requirement to review all NILM Pap tests in women with a current HSILþ Pap test result. However, most (72%; 234 of 324 reviewed all NILM Pap tests available in the previous 5 years, and many (63%; 197 of 315) include unsatisfactory Pap tests in that review. In the postsurvey, Web-based comments, 77% (20 of 26) of respondents reviewed all available slides (Pap tests and biopsies) in discordant cases; 19% (5 of 26) reviewed all available slides in both concordant and discordant cases. This may represent the sign-out practice for the group, where the last Pap test from that patient is automatically retrieved and paired with the biopsy slide before biopsy interpretation. Web-based respondents may represent cytologists that are more engaged with cytology processes and, therefore, more likely to take additional measures to satisfy their curiosity. The survey revealed that there is not much interlaboratory agreement on what constitutes a discordant pair deserving of remark in the biopsy report other than a HSIL Pap test/ normal biopsy or NILM Pap test/CIN 2-3 or greater biopsy (Table 5) , giving credence to permitting laboratories flexibility in defining discrepancies deserving of review. The data from the survey are confusing in part because multiple choices were allowed, and the question specifically asked only about discrepancies deserving of comment in a biopsy report. However, the survey data on what constitutes a positive correlation are not much better (Table 4) , but multiple choices were not allowed for that question, and the question did not specifically instruct respondents to ''check all that apply.'' Microscopic review of discrepant slides offers the greatest opportunity to detect and understand human interpretive errors as well as to identify sampling error. Real-time CHC may predispose observers to confirmation bias, where the observer tends to believe information that confirms their own preconceptions, despite the facts. An individual who interprets a CIN 3 biopsy may be predisposed to discover HSIL on a previously interpreted negative Pap test, when, in fact, the newly identified cells represent reactive metaplastic cells. Retrospective review can also be subject to bias if the observer is aware of the original interpretations of the discordant pair. There are ways to minimize bias for CHC. For real-time review, a second pathologist and/or cytotechnologist can review the discordant slides without knowledge of the initial result. Some laboratories routinely have a second pathologist review biopsies that do not correlate with prior Pap test results. During retrospective review of discrepant slides, one can prevent individual bias by collecting and reviewing all the noncorrelating Pap tests together without knowledge of the original interpretation or biopsy results. Similarly, reviewing all of the discordant biopsies in the same manner, without knowledge of the Pap test results or the initial biopsy interpretation, can minimize bias. After this exercise, the review interpretations can be correlated with the original results. If laboratories do not have policies to optimize the cervical biopsy before report certification, retrospective correlation provides an opportunity to take further sections from the block, reorient tissue in the block, apply ancillary studies, and investigate reasons other than interpretation for noncorrelation. Consensus Statement 8: CHC is optimum with a multilayered approach.
Conference participants overwhelmingly agreed that CHC should be performed using a multilayered approach that is suited to the laboratory size and staffing. This article describes a consensus approach to gynecologic CHC, which can serve as a focal point for laboratories to develop CHC programs. A multilayered, laboratory-directed approach to CHC can pinpoint potential problems and has the advantage of being tailored to circumstances. For some laboratories, CHC can be a tool to investigate interpretive variance, specimen quality, procurement adequacy, or other perceived trends as unveiled by other QA metrics. For other laboratories, the ability to perform robust CHC may be limited because of laboratory size or specimen volume (too small or too large), lack of access to certain slides, lack of follow-up information, LIS limitations, or insufficient staffing. A laboratory with one pathologist may have difficulty finding a second pathologist to confirm initial biopsy interpretations. Pathologists might consider having a cytotechnologist, other than the original cytotechnologist, reevaluate CHC Pap test slides. A study by Stelow et al 41 investigated the ''correctness'' of a cytopathologist or cytotechnologist for upgrading or downgrading Pap tests based on biopsy follow-up and found that cytotechnologists were more likely to correctly upgrade a Pap test. Each laboratory must develop a QA program based on its available resources and potential problems. Although a standardized PPV is an important metric for all laboratories to adopt as an initial interlaboratory comparison monitor, it is only the first step in the investigation of discordance between 2 specimens on the same patient. Laboratories can perform several different PPV measurements; some of which might include atypical squamous or glandular cells in the definition of TP. Laboratories may want to separate Pap test preparation types (conventional versus liquid-based preparations) to investigate differences in performance. Cytologic-histologic correlation can be performed without review of any patient slides, but it is slide review that harvests the most valuable information.
Additional laboratory-defined CHC metrics may be continuous or interval efforts. Interval CHC (not performed on a recurring basis) may target specific discrepant pairs for a predefined period to acquire a snapshot of laboratory performance for that indicator. For example, a laboratory may want to monitor the biopsy follow-up of its pregnant population with HSIL Pap tests for 2 years to determine the proportion of women who had CIN 2 or CIN 3 biopsies and adequate postpartum evaluation. Another may wish to monitor concordance of LSIL Pap test results with subsequent biopsy results for 3 months when the overall laboratory LSIL rate has increased. Other suggestions for interval monitors are listed in Table 11 . Review of glandular abnormalities can be particularly enlightening, and review of those slides can help to fine-tune diagnostic criteria and heighten awareness of these uncommon lesions. 42, 43 Continuous CHC (performed at routine intervals during the life of the laboratory) may be desirable for laboratories with high personnel turnover; disruptive environments, such as laboratory mergers; or mitigating circumstances outside of the laboratory's control that can affect overall performance. Continuous CHC has the advantage of detecting trends, provided the laboratory can periodically evaluate a standardized metric, such as PPV. Cytologic-histologic correlation findings should prompt further investigation when outliers occur. In the survey, laboratories indicated that they usually defined their own thresholds for determining when to investigate variances in CHC (Table 1 ) and very few used standard deviation from a performance mean. Significantly, laboratories also reported that they were unlikely to take corrective action because of CHC monitoring: only 15% (20 of 133) respondents took action. 5 This is not surprising, considering that the number of discrepancies in laboratories is generally small, many different individuals are involved in the process, and any single discrepancy does not necessarily indicate a problem in laboratory quality. It is also possible that laboratories were uncertain of what constitutes a reasonable corrective action. Pathologists were less likely to be corrected for discrepancies than cytotechnologists, but individual correction is not an uncommon laboratory response and might be shortsighted. Human interpretive error is not the only problem. It is often easier to blame an individual than to improve a system. Educational group review of difficult or discrepant cases is a favorite means of honing diagnostic skill and allows all individuals practicing cytology the opportunity to see low-prevalence lesions. Group review also places individuals in a more supportive environment, conducive to learning, as opposed to placing them in a defensive position when confronted with an error, provided a particular individual is not identified as making that error. Review of difficult patterns of HSIL on Pap tests, such as single, small, high nuclear to-cytoplasmic ratio cells and hyperchromatic, crowded groups, can emphasize the importance of recognizing those patterns during initial review. Laboratories should consider other ways of improving quality and investigating discrepancies found during CHC, methods that monitor the system as a whole (Table  12 ). For example, if cervical biopsies are routinely oriented poorly, so that the transformation zone is not captured in sections, FN biopsy results are likely to occur. A laboratory with this problem could standardize the method of biopsy embedding and enhance biopsy orientation by inking the endocervical pole. Papanicolaou test quality problems are not as prevalent with liquid-based preparations as with conventional Pap tests, but staining remains a potential reason for interpretive error for both preparations. Atrophic Pap tests always present challenges for recognizing dysplasia because of squamous immaturity and might be a reason for error in populations older than 50 years. Cytologichistologic correlation can also be a method for evaluating the detection efficacy of automated screening instruments by manually screening the slides for unselected abnormal cells.
Despite laboratory efforts to improve the quality of Pap tests and biopsies, discrepancies will continue to persist as long as caregivers providing the specimens remain remote from the QA process. Laboratories should consider providing adequacy statistics to caregivers, both for biopsy and Pap test procurement. Colposcopy conferences are useful to discuss the problems of procurement, processing, and interpretation. Sampling errors have not been significantly reduced for decades, perhaps because of the lack of coordination with, and feedback for, our clinical colleagues.
Conclusions
There are weaknesses to using a consensus process to determine good laboratory practices. Although this process did clarify existing practices through an initial survey of laboratories, the results mostly confirm that laboratories are complying with existing regulations and inspection guidelines-not an unexpected finding. This process did little to ferret out new or innovative quality practices in cytopathology. There is not much published evidence for the utility of some of the existing practices or for the consensus statements. We did not use a literature grading system to evaluate the strength of evidence when it was employed to draft consensus statements. How do these practices actually improve clinical patient outcomes? Is the investment in these practices worth the net gain? It is difficult to measure actual clinical outcomes and gains. Furthermore, consensus votes are sophisticated opinions and, even if based on experience and existing evidence, are subject to change with changing conditions. Consensus conferences limit the number of participants, so not all stakeholders are heard. It is difficult to obtain fair representation of every type of laboratory practice, and the ends of the spectrum-very large and very small laboratories-may be underrepresented. Many of the representatives and conference attendees were not working group members and were less familiar with existing data than the working groups were. This might have affected their final votes.
However, this process did solicit input from all US laboratories (n ¼ 1245) with a robust response (546 laboratories; 46% response) and from the laboratory community through surveys without prejudice to size or composition and probably accurately reflects current CHC practices. Consensus statements were designed based on those responses and were supported with existing literature. Finally, representatives of the laboratory community were able to vote on the statements in a forum where conference participants expressed sensitivity to the diverse practices and resources of laboratories.
The proposed CHC process is structured as a multilayered approach to QA. The consensus statements outline minimum correlation parameters. Additional investigation regarding correlation between paired specimens (Pap tests and biopsies) is suggested as ''laboratory-directed'' correlation. After evaluating initial correlation statistics over time, laboratories may decide to further investigate discrepancies that may be observed as trends. They may also implement ongoing correlation of specific paired specimens (eg, AGC Pap tests and cervical/endocervical/endometrial biopsies to detect glandular lesions). Such additional efforts may be continuous or interval monitors. Interval investigation may target specific pairs for a predefined period, such as for onequarter of a year, to acquire a snapshot of laboratory performance for that pair. Once problems are detected and the source identified, laboratories should implement changes in processes or policies to make permanent improvements to correct problems.
We recognize that Pap test and biopsy volume, access to paired specimens, access to biopsy or Pap test reports, practice variables and restrictions, and LISs differ among laboratories, making it difficult to define and impose mandatory guidelines for performance of CHCs. Furthermore, defining the appropriate statistical evaluation for each laboratory's data is problematic. Low-volume laboratories may not have enough correlation pairs to develop meaningful statistics for quarterly assessment and may need to collect data annually, whereas high-volume laboratories may wish to implement frequent correlation and statistical analyses for more timely detection and identification of problems. Additionally, microscopic review of the Pap test and biopsy slides, although optimal, may not be possible in situations where those slides are unavailable. In such situations, microscopic review of available slides is desirable, with the original interpretation of the unavailable paired specimen standing as the review interpretation for statistical purposes. Finally, CHC statistical results should be tabulated at least annually for all laboratories and evaluated for potential opportunities for improvement. 
